|
KMID : 0360319950270010092
|
|
Journal of Korean Cancer Research Association
1995 Volume.27 No. 1 p.92 ~ p.100
|
|
|
VACOP-B(VP-16, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) Chemotherapy for Non-Hodgkin's Lymphoma
|
|
길준영
최지영/윤환중/전의건/조덕연/김삼용
|
|
|
Abstract
|
|
|
Background:
@EN VACOP-B(VP-16, doxorubicin, vincristine, prednisone, and bleomycin), a regimen emphasizing weekly treatment and brief duration (12weeks), has been reported to be effective for the treatment of aggressive non-Hodgkin's lymphoma. We assessed
the
efficacy and the toxicity of VACOP-B treatment on an outpatient basis in patients with non-Hodgkin's lymphoma.
@ES Patients and Methods:
@EN Between August 1990 and August 1994, 25 patients with non-Hodgkin's lymphoma were treated with VACOP-B regimen on an outpatient basis. 23 of the 25 patients (92%)had intermediate-or high-grade lymphomas. Of the 23 evaluable patients, six
received
prior chemotherapy or radiation therapy.
@ES Results:
@EN Among the 23 evaluable patients, 19(76%)achieved a complete response and three (12%) achieved partial response. With a medinan follow-up of 24 months, survival ranged 2~44+ months. The acturial 3 year survival was 54%. Out of the 25 patients,
eight
(32%) experienced a marked leukopenia(<1,000/mm*), of whom seven required hospitalization due to infection, Non-hematologic toxicities were mild; grade I or Ⅱtoxicities were noticed (mucositis 36%; peripheral neuropathy 68%). Two died of the
toxicity
related to the chemotherapy(infection). Lower stage, complete response rather than partial response were associated with a longer survival.
@ES Conclusion:
@EN These results indicate that VACOP-B is effective, well tolerated, and feasible on an outpatient basis in the treatment of non-Hodgkin's lymphoma. The use of hemopoietic growth factors such as granulocyte-colony stimulating factor or
granulocyte-macrophage-colony stimulating factor might circumvent the leukopenia and facilitate delivery of chemotherapy at full doses.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|